KALA BIO, Inc.
KALA
$3.75
$0.030.81%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 18.34M | 18.76M | 19.31M | 19.96M | 20.57M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 40.43M | 40.32M | 41.25M | 40.86M | 39.15M |
Operating Income | -40.43M | -40.32M | -41.25M | -40.86M | -39.15M |
Income Before Tax | -38.51M | -38.96M | -38.72M | -39.55M | -42.20M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -38.51 | -38.96 | -38.72 | -39.55 | -42.20 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -38.51M | -38.96M | -38.72M | -39.55M | -42.20M |
EBIT | -40.43M | -40.32M | -41.25M | -40.86M | -39.15M |
EBITDA | -40.18M | -40.06M | -40.98M | -40.57M | -38.85M |
EPS Basic | -11.03 | -12.47 | -13.95 | -15.15 | -17.94 |
Normalized Basic EPS | -6.81 | -6.86 | -8.27 | -8.92 | -10.21 |
EPS Diluted | -11.04 | -12.48 | -13.95 | -15.15 | -17.94 |
Normalized Diluted EPS | -6.81 | -6.86 | -8.27 | -8.92 | -10.21 |
Average Basic Shares Outstanding | 15.17M | 13.18M | 11.11M | 10.46M | 9.72M |
Average Diluted Shares Outstanding | 15.17M | 13.18M | 11.11M | 10.46M | 9.72M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |